More about

Cervical Cancer

News
December 10, 2019
4 min read
Save

Expanding HPV vaccination to age 45 years not as cost-effective as current strategy

Expanding HPV vaccination to age 45 years not as cost-effective as current strategy

Expanding the current HPV vaccination program in the United States to include men and women up to age 45 years may only produce small additional benefits and is not nearly as cost-effective as it is among younger age groups, according to a study published in the Annals of Internal Medicine.

News
November 18, 2019
5 min read
Save

Cancer incidence not always the best measure of cancer trends

Cancer incidence not always the best measure of cancer trends

Cancer incidence rates represent one key measure of progress in the fight against cancer, but they are not the only consideration. According to a special report published in The New England Journal of Medicine, concordance between incidence and mortality rates provides a more complete picture of cancer burden.

News
October 01, 2019
2 min read
Save

Reduce stigma, improve education to increase cancer treatment among patients with HIV

Reduce stigma, improve education to increase cancer treatment among patients with HIV

Infectious Disease News Chief Medical Editor Paul A. Volberding, MD, spoke with Healio about which types of cancer patients with HIV are more likely to develop, how HIV treatments have changed that risk, how cancer affects HIV treatment and how to increase cancer treatment among these patients.

News
September 30, 2019
3 min read
Save

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.

News
September 25, 2019
2 min read
Save

Nivolumab shows promise in recurrent or metastatic cervical, vaginal/vulvar cancers

Nivolumab shows promise in recurrent or metastatic cervical, vaginal/vulvar cancers

Nivolumab showed promising efficacy among women with recurrent or metastatic cervical, vaginal or vulvar cancers, according to results from the single-arm phase 1/phase 2 CheckMate 358 trial published in Journal of Clinical Oncology.

News
August 09, 2019
3 min read
Save

Psychiatric disorders, stress increase risk for cervical cancer mortality

Psychiatric disorders, stress increase risk for cervical cancer mortality

Women with cervical cancer who experienced psychiatric disorders and stress around the time of diagnosis demonstrated higher rates of cancer-specific mortality than women without such distress at diagnosis, according to study results published in Cancer Research.

View more